A citation-based method for searching scientific literature

Shixue Chen, Zhibo Zhang, Xuan Zheng, Haitao Tao, Sujie Zhang, Junxun Ma, Zhefeng Liu, Jinliang Wang, Yuanyu Qian, Pengfei Cui, Di Huang, Ziwei Huang, Zhaozhen Wu, Yi Hu. Front Oncol 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki,[...]. Lancet Oncol 2019
250
50


Biostatistics primer: what a clinician ought to know: hazard ratios.
Helen Barraclough, Lorinda Simms, Ramaswamy Govindan. J Thorac Oncol 2011
29
50

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Ken Kato, Manish A Shah, Peter Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong-Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima,[...]. Future Oncol 2019
49
50

Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice.
Yu Chen, Yanqing Pei, Jingyu Luo, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng. Front Immunol 2020
11
50

When do changes in cancer survival mean progress? The insight from population incidence and mortality.
Hyunsoon Cho, Angela B Mariotto, Lisa M Schwartz, Jun Luo, Steven Woloshin. J Natl Cancer Inst Monogr 2014
81
50

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
Meredith K Chuk, Jennie T Chang, Marc R Theoret, Emmanuel Sampene, Kun He, Shawna L Weis, Whitney S Helms, Runyan Jin, Hongshan Li, Jingyu Yu,[...]. Clin Cancer Res 2017
55
50

Efficacy and safety of anti-PD-1/anti-PD-L1 antibody therapy in treatment of advanced gastric cancer or gastroesophageal junction cancer: A meta-analysis.
Li Yang, Xian-Zhe Dong, Xiao-Xuan Xing, Xiao-Hui Cui, Lin Li, Lan Zhang. World J Gastrointest Oncol 2020
3
50

Quantifying publication bias in meta-analysis.
Lifeng Lin, Haitao Chu. Biometrics 2018
195
50



A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
Rimei Nishimura, Takeshi Osonoi, Yasuhiro Koike, Kouji Miyata, Yukio Shimasaki. Adv Ther 2019
9
50

Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.
Ramon Andrade De Mello, Florian Lordick, Kei Muro, Yelena Y Janjigian. Am Soc Clin Oncol Educ Book 2019
11
50



PD-1/PD-L1 pathway: current researches in cancer.
Yanyan Han, Dandan Liu, Lianhong Li. Am J Cancer Res 2020
130
50

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Takashi Kojima, Manish A Shah, Kei Muro, Eric Francois, Antoine Adenis, Chih-Hung Hsu, Toshihiko Doi, Toshikazu Moriwaki, Sung-Bae Kim, Se-Hoon Lee,[...]. J Clin Oncol 2020
116
50


Practical methods for incorporating summary time-to-event data into meta-analysis.
Jayne F Tierney, Lesley A Stewart, Davina Ghersi, Sarah Burdett, Matthew R Sydes. Trials 2007
50


Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
107
50

Esophageal Cancer.
Matthew W Short, Kristina G Burgers, Vincent T Fry. Am Fam Physician 2017
93
50

GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem, Mark Helfand, Holger J Schünemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris,[...]. J Clin Epidemiol 2011
50

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
50

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
Matthew J Page, Joanne E McKenzie, Patrick M Bossuyt, Isabelle Boutron, Tammy C Hoffmann, Cynthia D Mulrow, Larissa Shamseer, Jennifer M Tetzlaff, Elie A Akl, Sue E Brennan,[...]. BMJ 2021
50

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Yelena Y Janjigian, Kohei Shitara, Markus Moehler, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda Campos Bragagnoli,[...]. Lancet 2021
44
50


Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
Gideon M Blumenthal, Stella W Karuri, Hui Zhang, Lijun Zhang, Sean Khozin, Dickran Kazandjian, Shenghui Tang, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur. J Clin Oncol 2015
125
50

Chemotherapy for advanced gastric cancer.
Anna Dorothea Wagner, Nicholas Lx Syn, Markus Moehler, Wilfried Grothe, Wei Peng Yong, Bee-Choo Tai, Jingshan Ho, Susanne Unverzagt. Cochrane Database Syst Rev 2017
289
50

PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy.
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, Saeed Aslani, Malihe Alimardani, Alireza Pasdar, Amirhossein Sahebkar. J Cell Physiol 2019
115
50

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials.
Zaishang Li, Xueying Li, Wayne Lam, Yabing Cao, Hui Han, Xueqi Zhang, Jiequn Fang, Kefeng Xiao, Fangjian Zhou. Front Oncol 2021
1
100

Analysis of data from multiclinic trials.
J L Fleiss. Control Clin Trials 1986
268
50

Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan,[...]. Lancet Oncol 2020
69
50


Assessing heterogeneity in meta-analysis: Q statistic or I2 index?
Tania B Huedo-Medina, Julio Sánchez-Meca, Fulgencio Marín-Martínez, Juan Botella. Psychol Methods 2006
50

Sample size and power considerations in network meta-analysis.
Kristian Thorlund, Edward J Mills. Syst Rev 2012
75
50

Epidemiology of gastric cancer: global trends, risk factors and prevention.
Prashanth Rawla, Adam Barsouk. Prz Gastroenterol 2019
327
50

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Ronan J Kelly, Jaffer A Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, Josephine Feliciano, Satoru Motoyama, Astrid Lièvre,[...]. N Engl J Med 2021
82
50

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
Julian P T Higgins, Douglas G Altman, Peter C Gøtzsche, Peter Jüni, David Moher, Andrew D Oxman, Jelena Savovic, Kenneth F Schulz, Laura Weeks, Jonathan A C Sterne. BMJ 2011
50

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
493
50

Comparative Efficacy and Safety of Programmed Death-1 Pathway Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Network Meta-Analysis of Phase III Clinical Trials.
Laercio Lopes da Silva, Pedro Nazareth Aguiar, Robin Park, Eduardo Edelman Saul, Benjamin Haaland, Gilberto de Lima Lopes. Cancers (Basel) 2021
3
50


Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Jianchun Duan, Longgang Cui, Xiaochen Zhao, Hua Bai, Shangli Cai, Guoqiang Wang, Zhengyi Zhao, Jing Zhao, Shiqing Chen, Jia Song,[...]. JAMA Oncol 2020
93
50


Clinical implications of tumor-intrinsic mechanisms regulating PD-L1.
Alessandro Prestipino, Robert Zeiser. Sci Transl Med 2019
20
50

On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
Alexander M Lesokhin, Margaret K Callahan, Michael A Postow, Jedd D Wolchok. Sci Transl Med 2015
107
50

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima. Front Oncol 2018
412
50


The role of PD-1 in regulation of macrophage apoptosis and its subversion by Leishmania donovani.
Shalini Roy, Purnima Gupta, Shreyasi Palit, Moumita Basu, Anindita Ukil, Pijush K Das. Clin Transl Immunology 2017
17
50

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.
Robert D Schreiber, Lloyd J Old, Mark J Smyth. Science 2011
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.